[1]张献方,孟凡亮.CD47蛋白的表达与非小细胞肺癌预后的相关性研究[J].医学信息,2023,36(12):96-101.[doi:10.3969/j.issn.1006-1959.2023.12.018]
　ZHANG Xian-fang,MENG Fan-liang.Correlation Between the Expression of CD47 Protein and the Prognosis of Non-small Cell Lung Cancer[J].Journal of Medical Information,2023,36(12):96-101.[doi:10.3969/j.issn.1006-1959.2023.12.018]
点击复制

CD47蛋白的表达与非小细胞肺癌预后的相关性研究()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
36卷
期数:
2023年12期
页码:
96-101
栏目:
论著
出版日期:
2023-06-15

文章信息/Info

Title:
Correlation Between the Expression of CD47 Protein and the Prognosis of Non-small Cell Lung Cancer
文章编号:
1006-1959（2023）12-0096-06
作者:
张献方; 孟凡亮
（安徽医科大学附属巢湖医院呼吸内科，安徽 巢湖 238000）
Author(s):
ZHANG Xian-fang; MENG Fan-liang
(Department of Respiratory Medicine,Chaohu Hospital of Anhui Medical University,Chaohu 238000,Anhui,China)
关键词:
非小细胞肺癌; 免疫组化; CD47; PD-L1; 免疫疗法
Keywords:
Non-small cell lung cancer; Immunohistochemistry; CD47; PD-L1; Immunotherapy
分类号:
R734.2
DOI:
10.3969/j.issn.1006-1959.2023.12.018
文献标志码:
A
摘要:
目的 研究CD47的表达与临床特征的相关性，揭示CD47在非小细胞肺癌中的预后意义，验证CD47和PD-L1的关系。方法 收集2015年1月1日-2019年10月1日就诊于安徽医科大学附属巢湖医院的50例非小细胞肺癌患者的术后肿瘤组织以及20例癌旁组织进行CD47的免疫组化检测，分析CD47表达与患者临床病理特征和预后的相关性。TCGA数据库用于识别CD47和PD-L1之间的关联。结果 CD47在非小细胞肺癌组织的阳性表达率高于癌旁组织，差异有统计学意义（P＜0.05）；CD47蛋白在临床分期晚、有淋巴结转移的非小细胞肺癌患者中高于临床分期早、无淋巴结转移的非小细胞肺癌患者，差异有统计学意义（P＜0.05），而不同年龄、性别、吸烟史、病理类型、分化程度间CD47蛋白表达比较，差异无统计学意义（P＞0.05）；CD47阳性表达组无进展生存期短于CD47阴性表达组，差异有统计学意义（P＜0.05），且CD47蛋白表达水平和临床分期与PFS具有相关性（P＜0.05）；CD47和PD-L1在肺腺癌和肺鳞癌中高表达（P＜0.05）。结论 高CD47表达与NSCLC发生、转移及不良预后有关，对患者预后有预测价值。CD47和PD-L1联合检测是非小细胞肺癌联合免疫治疗的潜在靶点。
Abstract:
Objective To study the correlation between the expression of CD47 and clinical features, to reveal the prognostic significance of CD47 in non-small cell lung cancer, and to verify the relationship between CD47 and PD-L1.Methods Collect the postoperative tumor tissues of 50 patients with non-small cell lung cancer and 20 adjacent tissues from January 1, 2015 to October 1, 2019 in Chaohu Hospital of Anhui Medical University for immunohistochemical detection of CD47, and the correlation between CD47 expression and clinicopathological features and prognosis of patients was analyzed. The TCGA database was used to identify the association between CD47 and PD-L1.Results The positive expression rate of CD47 in non-small cell lung cancer tissues was higher than that in adjacent tissues, and the difference was statistically significant (P<0.05). The expression of CD47 protein in non-small cell lung cancer patients with late clinical stage and lymph node metastasis was higher than that in non-small cell lung cancer patients with early clinical stage and no lymph node metastasis, and the difference was statistically significant (P<0.05). There was no significant difference in the expression of CD47 protein between different age, sex, smoking history, pathological type and differentiation degree (P>0.05). The pro-gression-free survival of CD47 positive expression group was shorter than that of CD47 negative expression group, and the difference was statistically significant (P<0.05), while the expression level of CD47 protein and clinical stage were correlated with PFS (P<0.05). CD47 and PD-L1 were highly expressed in lung adenocarcinoma and lung squamous cell carcinoma (P<0.05).Conclusion The high expression of CD47 is related to the occurrence, metastasis and poor prognosis of NSCLC, which is of prognostic value. The combined detection of CD47 and PD-L1 is a potential target for combined immunotherapy of NSCLC.

参考文献/References:

[1]Jonna S,Subramaniam DS.Molecular diagnostics and targeted therapies in non-small cell lung cancer (NSCLC): an update[J].Discov Med,2019,27(148):167-170.[2]Imai H,Onozato R,Kaira K,et al.Course of postoperative relapse in non-small cell lung cancer is strongly associated with post-progression survival[J].Thorac Cancer,2021,12(20):2740-2748.[3]Bouwstra R,van Meerten T,Bremer E.CD47-SIRPα blocking-based immunotherapy: Current and prospective therapeutic strategies[J].Clin Transl Med,2022,12(8):e943.[4]Dizman N,Buchbinder EI.Cancer Therapy Targeting CD47/SIRPα[J].Cancers (Ba-sel),2021,13(24):6229.[5]Zhou F,Feng B,Yu H,et al.Tumor Microenvironment-Activatable Prodrug Vesicles for Nanoenabled Cancer Chemoimmunotherapy Combining Immunogenic Cell Death Induction and CD47 Blockade[J].Adv Mater,2019,31(14):e1805888.[6]Chen C,Wang R,Chen X,et al.Targeting CD47 as a Novel Immunotherapy for Breast Cancer[J].Front Oncol,2022,12:924740.[7]Zhou Y,Zeng J,Zhou W,et al.Prognostic significance of CKS2 and CD47 expression in patients with gastric cancer who underwent radica gastrectomy[J].Scand J Immunol,2022,96(4):e13198.[8]Yang K,Xu J,Liu Q,et al.Expression and significance of CD47,PD1 and PDL1 in T-cell acute lymphoblastic lymphoma/leukemia[J].Pathol Res Pract,2019,215(2):265-271.[9]Duma N,Santana-Davila R,Molina JR.Non-Small Cell Lung Cancer: Epidemiolo-gy,Screening,Diagnosis,and Treatment[J].Mayo Clin Proc,2019,94(8):1623-1640.[10]Baran K,Brzeziańska-Lasota E.Proteomic biomarkers of non-small cell lung cancer pa-tients[J].Adv Respir Med,2021,89(4):419-426.[11]Jia X,Yan B,Tian X,et al.CD47/SIRPα pathway mediates cancer immune escape and immuno-therapy[J].Int J Biol Sci,2021,17(13):3281-3287.[12]Liu X,Kwon H,Li Z,et al.Is CD47 an innate immune checkpoint for tumor evasion?[J].J Hematol Oncol,2017,10(1):12.[13]Xu Y,Li J,Tong B,et al.Positive tumour CD47 expression is an independent prognostic factor for recurrence in resected non-small cell lung cancer[J].ESMO Open,2020,5(4):e000823.[14]Zhao H,Wang J,Kong X,et al.CD47 Promotes Tumor Invasion and Metastasis in Non-small Cell Lung Cancer[J].Sci Rep,2016,6:29719.[15]Song G,Yang L.Inhibited CD47 gene affects the clearance of acute myelogenous leukemia stem cells[J].J Cell Biochem,2019,120(6):10303-10309.[16]Fu F,Zhang Y,Gao Z,et al.Combination of CD47 and CD68 expression predicts survival in eastern-Asian patients with non-small cell lung cancer[J].J Cancer Res Clin On-col,2021,147(3):739-747.[17]Wang X,Wang Y,Hu J,et al.An antitumor peptide RS17-targeted CD47,design,synthesis,and antitumor activity[J].Cancer Med,2021,10(6):2125-2136.[18]Rao L,Wu L,Liu Z,et al.Hybrid cellular membrane nanovesicles amplify macrophage immune responses against cancer recurrence and metastasis[J].Nat Commun,2020,11(1):4909.[19]Zhang W,Huang Q,Xiao W,et al.Advances in Anti-Tumor Treatments Targeting the CD47/SIRPα Axis[J].Front Immunol,2020,11:18.[20]Yang Y,Yang Z,Yang Y.Potential Role of CD47-Directed Bispecific Antibodies in Cancer Immunotherapy[J].Front Immunol,2021,12:686031.[21]Casey SC,Tong L,Li Y,et al.MYC regulates the antitumor immune response through CD47 and PD-L1[J].Science,2016,352(6282):227-231.

相似文献/References:

[1]田 亮,郭 楠,苗志刚,等.非小细胞肺癌中ZEB1和FoxO3a表达及意义[J].医学信息,2018,31(03):16.[doi:10.3969/j.issn.1006-1959.2018.03.006]
　TIAN Liang,GUO Nan,MIAO Zhi-gang,et al.Expression and Significance of ZEB1 and FoxO3a in Non-small Cell Lung Cancer[J].Journal of Medical Information,2018,31(12):16.[doi:10.3969/j.issn.1006-1959.2018.03.006]
[2]杜秋越,刘易欣,陈 凌.免疫组化指标在宫颈微偏腺癌诊断中的应用[J].医学信息,2018,31(09):53.[doi:10.3969/j.issn.1006-1959.2018.09.017]
　DU Qiu-yue,LIU Yi-xin,CHEN Ling.Application of Immunohistochemical Markers in Diagnosis of Minimal Deviationadenocarcinoma of Cervix[J].Journal of Medical Information,2018,31(12):53.[doi:10.3969/j.issn.1006-1959.2018.09.017]
[3]张小龙.P53在胆囊癌临床预后中的预测意义[J].医学信息,2018,31(11):156.[doi:10.3969/j.issn.1006-1959.2018.11.051]
　ZHANG Xiao-long.Predictive Significance of P53 in Clinical Prognosis of Gallbladder Carcinoma[J].Journal of Medical Information,2018,31(12):156.[doi:10.3969/j.issn.1006-1959.2018.11.051]
[4]陶 洪,孙国平.非小细胞肺癌根治术后复发及进展影响因素的回顾性分析[J].医学信息,2018,31(12):61.[doi:10.3969/j.issn.1006-1959.2018.12.019]
　TAO Hong,SUN Guo-ping.Retrospective Analysis of Factors Influencing Recurrence and Progression after Radical Resection of Non-small Cell Lung Cancer[J].Journal of Medical Information,2018,31(12):61.[doi:10.3969/j.issn.1006-1959.2018.12.019]
[5]李春磊,裴艳志,邹志田,等.非小细胞肺癌组织中趋化因子受体CCR7的 表达及其临床意义[J].医学信息,2018,31(17):14.[doi:10.3969/j.issn.1006-1959.2018.17.004]
　LI Chun-lei,PEI Yan-zhi,ZOU Zhi-tian,et al.Expression of Chemokine Receptor CCR7 in Non-small Cell Lung Cancer and its Clinical Significance[J].Journal of Medical Information,2018,31(12):14.[doi:10.3969/j.issn.1006-1959.2018.17.004]
[6]杨 莉.TP方案联合回生口服液治疗中晚期非小细胞肺癌的疗效观察[J].医学信息,2018,31(17):17.[doi:10.3969/j.issn.1006-1959.2018.17.005]
　YANG Li.Therapeutic Effect of TP Regimen Combined with Huisheng Oral Liquid in the Treatment of Advanced Non-small Cell Lung Carcinoma[J].Journal of Medical Information,2018,31(12):17.[doi:10.3969/j.issn.1006-1959.2018.17.005]
[7]田春琴,赵新汉,蒋冬梅,等.二线用药EGFR-TKIs治疗非选择型NSCLC疗效的Meta分析[J].医学信息,2018,31(20):49.[doi:10.3969/j.issn.1006-1959.2018.20.015]
　TIAN Chun-qin,ZHAO Xin-han,JIANG Dong-mei,et al.Meta-analysis of the Efficacy of Second-line EGFR-TKIs in the Treatment of Nonselective NSCLC[J].Journal of Medical Information,2018,31(12):49.[doi:10.3969/j.issn.1006-1959.2018.20.015]
[8]徐闻霞,陆红艳,黄 斌.胸腔镜肺叶切除和肺段切除治疗ⅠA期非小细胞肺癌的疗效比较[J].医学信息,2018,31(21):100.[doi:10.3969/j.issn.1006-1959.2018.21.027]
　XU Wen-xia,LU Hong-yan,HUANG Bin.Comparison of Thoracoscopic Lobectomy and Segmentectomy for ⅠA Non-small Cell Lung Cancer[J].Journal of Medical Information,2018,31(12):100.[doi:10.3969/j.issn.1006-1959.2018.21.027]
[9]付红星,冯小剑,彭文苗,等.康艾注射液联合化疗治疗晚期非小细胞肺癌的临床研究[J].医学信息,2018,31(24):115.[doi:10.3969/j.issn.1006-1959.2018.24.033]
　FU Hong-xing,FENG Xiao-jian,PENG Wen-miao,et al.Clinical Study of Kang'ai Injection Combined with Chemotherapy in the Treatment of Advanced Non-small Cell Lung Cancer[J].Journal of Medical Information,2018,31(12):115.[doi:10.3969/j.issn.1006-1959.2018.24.033]
[10]吴森林,高 斌.中性粒细胞/淋巴细胞比值与介入治疗中晚期非小细胞肺癌患者预后的相关性[J].医学信息,2019,32(03):82.[doi:10.3969/j.issn.1006-1959.2019.03.025]
　WU Sen-lin,GAO Bin.Correlation between Neutrophil/Lymphocyte Ratio and Prognosis in Patients with Advanced Non-small Cell Lung Cancer[J].Journal of Medical Information,2019,32(12):82.[doi:10.3969/j.issn.1006-1959.2019.03.025]
[11]谢明珠,朱洪斌,朱 楠,等.CPSF6在晚期非小细胞肺癌中的表达及与预后的关系[J].医学信息,2024,37(04):95.[doi:10.3969/j.issn.1006-1959.2024.04.017]
　XIE Ming-zhu,ZHU Hong-bin,ZHU Nan,et al.Expression of CPSF6 in Advanced Non-small Cell Lung Cancer and its Relationship with Prognosis[J].Journal of Medical Information,2024,37(12):95.[doi:10.3969/j.issn.1006-1959.2024.04.017]

更新日期/Last Update: 1900-01-01